Literature DB >> 35229693

Subjective cognitive decline, APOE e4 allele, and the risk of neurocognitive disorders: Age- and sex-stratified cohort study.

Tau Ming Liew1,2.   

Abstract

OBJECTIVE: Subjective cognitive decline and APOE e4 allele (APOE4) are known predictors of mild cognitive impairment and dementia (mild cognitive impairment/dementia), with recent evidence showing interaction between subjective cognitive decline and APOE4 in amplifying the risk of mild cognitive impairment/dementia. However, the literature is unclear whether the interaction effect is seen across various age and sex strata. This study examined the interaction between subjective cognitive decline and APOE4-across different age and sex strata-on the risk of mild cognitive impairment/dementia.
METHODS: This cohort study included 16,221 participants aged ⩾50 years and had normal cognition at baseline. Participants were evaluated for subjective cognitive decline and APOE4 at baseline, and followed-up almost annually for mild cognitive impairment/dementia (median follow-up = 4.5 years). Interaction effects were examined in Cox regression using Relative Excess Risk due to Interaction, stratified by age (⩽70 vs >70 years) and sex.
RESULTS: Subjective cognitive decline and APOE4 were independently associated with mild cognitive impairment/dementia (hazard ratio: 1.4-1.8), with the highest risk when subjective cognitive decline and APOE4 co-occurred (hazard ratio: 2.6). APOE4 amplified the association between subjective cognitive decline and mild cognitive impairment/dementia in older women (Relative Excess Risk due to Interaction 1.0; 95% confidence interval = [0.3, 1.6]), but not in other age or sex strata. Among older women, half of them developed mild cognitive impairment/dementia by 12.1 years in the absence of subjective cognitive decline or APOE4. This duration shortened to 8.1-10.3 years in the presence of either subjective cognitive decline or APOE4, and to 4.4 years in the presence of both subjective cognitive decline and APOE4. Interaction effect among older women remained consistent when alternate outcomes were used (i.e. mild cognitive impairment and dementia due to Alzheimer's disease; dementia; and Alzheimer's dementia) (Relative Excess Risk due to Interaction 1.2-2.5).
CONCLUSIONS: APOE4 amplifies the association between subjective cognitive decline and neurocognitive disorders in older women, with the findings suggesting the need for further research to delineate underlying neurobiology. APOE4 may potentially have a role in facilitating further risk stratification of older women with subjective cognitive decline in clinical practice.

Entities:  

Keywords:  Subjective memory complaints; apolipoprotein; dementia; longitudinal study; mild cognitive impairment

Year:  2022        PMID: 35229693      PMCID: PMC9433458          DOI: 10.1177/00048674221079217

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.598


  46 in total

1.  Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis.

Authors:  Scott C Neu; Judy Pa; Walter Kukull; Duane Beekly; Amanda Kuzma; Prabhakaran Gangadharan; Li-San Wang; Klaus Romero; Stephen P Arneric; Alberto Redolfi; Daniele Orlandi; Giovanni B Frisoni; Rhoda Au; Sherral Devine; Sanford Auerbach; Ana Espinosa; Mercè Boada; Agustín Ruiz; Sterling C Johnson; Rebecca Koscik; Jiun-Jie Wang; Wen-Chuin Hsu; Yao-Liang Chen; Arthur W Toga
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

2.  Developing a Brief Neuropsychological Battery for Early Diagnosis of Cognitive Impairment.

Authors:  Tau Ming Liew
Journal:  J Am Med Dir Assoc       Date:  2019-04-13       Impact factor: 4.669

Review 3.  Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease.

Authors: 
Journal:  JAMA       Date:  1995 Nov 22-29       Impact factor: 56.272

4.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

Review 5.  Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies.

Authors:  Breno S Diniz; Meryl A Butters; Steven M Albert; Mary Amanda Dew; Charles F Reynolds
Journal:  Br J Psychiatry       Date:  2013-05       Impact factor: 9.319

Review 6.  Sex differentials in health.

Authors:  L M Verbrugge
Journal:  Public Health Rep       Date:  1982 Sep-Oct       Impact factor: 2.792

Review 7.  Involvement of Lipids in Alzheimer's Disease Pathology and Potential Therapies.

Authors:  Hannah Chew; Victoria A Solomon; Alfred N Fonteh
Journal:  Front Physiol       Date:  2020-06-09       Impact factor: 4.566

8.  Subjective cognitive decline, APOE ε4, and incident mild cognitive impairment in men and women.

Authors:  Diana Müller-Gerards; Christian Weimar; Jessica Abramowski; Sarah Tebrügge; Martha Jokisch; Nico Dragano; Raimund Erbel; Karl-Heinz Jöckel; Susanne Moebus; Angela Winkler
Journal:  Alzheimers Dement (Amst)       Date:  2019-03-06

9.  Depression, subjective cognitive decline, and the risk of neurocognitive disorders.

Authors:  Tau Ming Liew
Journal:  Alzheimers Res Ther       Date:  2019-08-09       Impact factor: 6.982

10.  Defining Disease Modifying Therapy for Alzheimer's Disease.

Authors:  J Cummings; N Fox
Journal:  J Prev Alzheimers Dis       Date:  2017-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.